1. At a Glance
Hester Biosciences Ltd, the ₹1,429 crore microcap vaccine warrior of Ahmedabad, just posted a quarter that looked like a Bollywood comeback arc — dramatic, emotional, and finally profitable. The company reported ₹71 crore in revenue and ₹14.4 crore in PAT for Q2 FY26, a 76% YoY profit jump, even as sales fell 15%. How? Because animal viruses may spread fast, but so does margin improvement.
At ₹1,680 a share, the stock trades at a P/E of 32.6x — premium pricing for a company selling goat vaccines and cattle injections. ROE stands at 9.18%, ROCE at 9.71%, and debt of ₹214 crore keeps bankers awake at night but shareholders mildly amused. The dividend yield is 0.42%, just enough to buy one samosa per share annually.
On the bright side, the company has zero pledges, 53.7% promoter holding, and a monopoly-like grip on rural immunization:
- 75% global share in PPR vaccine,
- 70%+ in Goat Pox, and
- 35% of India’s poultry vaccine market.
And just when the birds started chirping again, CFO Divyesh Maru dropped his resignation letter on 13 November 2025. Maybe he saw too many “H9N2 approvals expected in December” notes and thought, “I’m out.”
Still, the Bhagavad Gita says, “Do your duty without attachment to results.” Hester seems to have taken that literally — focusing on vaccines while ignoring stock returns.
2. Introduction – The Vaccine Vada Pav
If Serum Institute is the Ambani of vaccines, Hester is the street-smart Gujarati cousin selling immunity by the dose. Founded in 1987 by Mr. Rajiv Gandhi (no, not that one), the company went from local poultry vaccines to a global player with operations in India, Nepal, and Tanzania, distributing across 35+ countries.
But FY25 and FY26 have been more like a farmer’s monsoon story — unpredictable but hopeful. Poultry sales fell due to weak farm economics, yet animal vaccines picked up pace thanks to outbreaks like Lumpy Skin Disease in cattle. In the vaccine business, someone’s misery is another’s market share.
Hester isn’t your typical pharma play. It’s rural India meets R&D — a desi biotech balancing goats, chickens, and regulatory filings. While most healthcare companies target humans, Hester targets the creatures that feed those humans. You could say it’s the unsung link in India’s food chain economy.
And if that’s not dramatic enough, it’s also backed by some impressive collaborations — Bill & Melinda Gates Foundation, GALVmed, OIE, and Novapharma Egypt. That’s like the Avengers assembling, but for goats.
3. Business Model – WTF Do They Even Do?
At its core, Hester sells hope to farmers and immunity to livestock. It runs through four business verticals that sound simple until you realize each is regulated like a
